Lipid Compounds for Retinal Delivery via Topical Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal disorders such as age-related macular degeneration and diabetic retinopathy are limited, with no effective treatments for the dry form of AMD and significant adverse effects from intravitreal injections, necessitating the development of alternative drug candidates that can accumulate in the retina following topical administration.
Innovation Solution
Development of novel omega-6 polyunsaturated fatty acid derivatives with good PPARα activating properties, which protect against oxidative stress-induced mtDNA damage, thereby attenuating disease progression in retinal disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravitreal injections are used to treat retinal disorders, then treatment effectiveness is improved, but adverse effects and patient burden increase
Solution Approach 1:
The patent uses fatty acid derivatives as intermediary compounds that can be administered topically and accumulate in the retina through natural physiological processes, avoiding direct injection into the eye while still achieving therapeutic concentrations at the target site
Solution Approach 2:
The patent replaces the mechanical injection system with a topical administration system using lipid compounds that utilize biological transport mechanisms (such as incorporation into lipoproteins and accumulation in retinal tissue) to deliver the active ingredient to the retina without physical penetration
2Ease of operation
If topical administration is used for retinal treatment, then patient comfort and accessibility are improved, but drug accumulation in the retina is insufficient
Solution Approach 1:
The patent modifies the chemical parameters of the drug molecules by using fatty acid derivatives with specific chain lengths, degrees of unsaturation, and functional groups that match the composition of retinal lipids, enabling these compounds to be naturally incorporated into retinal tissue and accumulate to therapeutic levels
Solution Approach 2:
The patent utilizes the body's natural lipid metabolism and transport systems to carry the fatty acid derivatives to the retina, where they are incorporated into cellular membranes and stored, effectively using the body's own transport machinery to overcome the limitation of topical administration
3Reliability
If systemic doses are increased to achieve adequate retinal concentrations, then treatment efficacy is improved, but systemic side effects increase
Solution Approach 1:
The patent creates local concentration of the therapeutic agent in the retina through selective accumulation of fatty acid derivatives in retinal tissue, while maintaining low systemic concentrations that do not cause adverse effects elsewhere in the body
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives effectively protect retinal pigment epithelial cells from apoptosis, providing a potential treatment for degenerative eye diseases like AMD, Stargardt's disease, and other ocular inflammatory disorders, offering a more affordable and accessible treatment option with reduced systemic side effects.
Implementation Method 1
protect against oxidative stress-induced mtDNA damage
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The invention relates to lipid compounds of formula (I) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R1 is either a C9 to C22 alkyl group, or a C9 to C22 alkenyl group having from 1 to 6 double bonds; R2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R3 is a hydrogen atom, or a group R2; R4 is a carboxylic acid or a derivative thereof; and X is methylene (-CH2-), or an oxygen or sulfur atom).